BioCentury
ARTICLE | Clinical News

AzaSite Plus: Completed Phase III enrollment

September 24, 2012 7:00 AM UTC

InSite completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 days. InSite has an SPA from FDA for DOUBle. ...